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Abstract: The risk of venous thromboembolism (VTE) in patients undergoing total knee or hip replacement surgery is 
high. As a result, thromboprophylaxis is highly recommended. While current thromboprophylactic agents, such as low 
molecular weight heparins (LMWH) and vitamin K antagonists, are safe and effective their use can be problematic. 
Therefore, there is a need for alternative anticoagulants that are as safe and effective as conventional agents, but are more 
convenient and easier to use. Dabigatran etexilate, a direct thrombin inhibitor, is one such anticoagulant. For VTE 
prevention following major orthopaedic surgery, dabigatran etexilate shows similar efficacy and safety to the LMWH 
enoxaparin, and is approved for use in more than 75 countries, including Europe and Canada. Here, we summarize and 
discuss the experiences of four German clinics that have recently introduced dabigatran etexilate into clinical practice. 
Overall, dabigatran etexilate was well received by patients, surgeons and nurses, and compared favourably with 
enoxaparin. Staff appreciated the oral, single-dose administration of dabigatran etexilate. Patient satisfaction was high, 
especially in those individuals who had previously used LMWHs. In this review, we also address a number of questions 
that were asked by patients or staff; this will be of relevance to orthopaedic surgeons and nurses. We conclude that, in 
these four German clinics, dabigatran etexilate offered an effective oral alternative to existing thromboprophylactic agents 
in patients undergoing major orthopaedic surgery. 
Keywords: Anticoagulant, Dabigatran etexilate, Direct thrombin inhibitor, Hip replacement surgery, Knee replacement 
surgery, Thromboprophylaxis. 
INTRODUCTION 
  Despite the clear benefits of thromboprophylaxis, venous 
thromboembolism (VTE) remains one of the most common 
causes of re-hospitalization in orthopaedic surgery patients 
[1, 2]. Here, we briefly review current thromboprophylaxis 
and report the experience of four German clinics that have 
implemented prophylaxis with the recently introduced oral 
direct thrombin inhibitor dabigatran etexilate. 
THE NEED FOR THROMBOPROPHYLAXIS FOLLO-
WING ORTHOPAEDIC SURGERY 
  Patients undergoing primary or secondary elective total 
hip replacement (THR) or total knee replacement (TKR) 
surgery have a high risk of VTE, which presents as 
symptomatic deep vein thrombosis or pulmonary embolism 
[3]. VTE may also be asymptomatic but detectable by 
venography. Without thromboprophylaxis ~40–60% of these 
patients will develop objectively confirmed, hospital-acqu-
ired, asymptomatic, or symptomatic deep vein thrombosis 
[4]. Hence, since 1986, treatment with thromboprophylactic 
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agents has been recommended for patients undergoing major 
orthopaedic surgery [5]. Fatal pulmonary embolism occurs in 
1 of every 300 patients following THR without 
thromboprophylaxis, although events are rare if guideline-
recommended anticoagulants are administered [4]. 
  Postoperative VTE is associated with considerable 
morbidity and mortality [6-9], and the ever-increasing 
number of THR and TKR procedures being performed could 
also increase the incidence of these VTE-related events [10-
13]. Using statistical projections based on the increase in 
procedures between 1990 and 2003, it has been estimated 
that the demand for THR procedures in the USA could 
increase by 174% from 209,000 in 2005 to 572,000 by 2030; 
the demand for TKR procedures could increase by 673% 
from 450,000 in 2005 to 3.48 million by 2030 [12]. These 
estimates help to illustrate the scale of the current and future 
challenge of postoperative VTE prevention that also exists in 
Europe. In Germany, for instance, 223,000 THR and 
157,000 TKR operations were conducted in 2008 [14]. 
Furthermore, it is predicted that in Germany and most other 
European countries, the number of primary and secondary 
total joint replacement surgeries will increase over the next 
few decades [14]. 
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THROMBOPROPHYLACTIC AGENTS 
  Traditionally, thromboprophylaxis has been provided 
with low molecular weight heparins (LMWH) or vitamin K 
antagonists, such as phenprocoumon, acenocoumarol and 
warfarin. Although such medications are effective, there are 
several limitations associated with their use. LMWH are 
parenteral agents and, therefore, their administration can be 
problematic (especially outside the hospital environment) 
and may incur additional costs [15]. In addition, heparin-
induced thrombocytopenia can occur with LMWH, although 
the risk is thought to be lower with LMWH than with 
unfractionated heparin [16]; the incidence of heparin-
induced thrombocytopenia has been reported to be 0–0.9% 
in orthopaedic surgery patients treated with LMWH and 3–
5% in those treated with unfractionated heparin [17]. The 
condition is associated with a risk of thrombotic events 30 
times that of control populations and hence can result in 
considerable mortality and morbidity [17, 18]. Warfarin and 
other vitamin K antagonists, which have tended to be used 
more in the USA than in Europe, require routine 
anticoagulation monitoring and dose adjustment, and have 
numerous food and drug interactions [19]. Vitamin K 
antagonists do, however, have a relative price advantage 
over LMWH. 
  Due to these relative drawbacks of existing therapies, 
there is a need for new anticoagulants that are safe, effective 
and overcome these challenges [15]. Two new oral 
antithrombotics, dabigatran etexilate and rivaroxaban, have 
been approved and established in clinical use within 
Germany for exclusive use in primary THR and TKR. 
Dabigatran Etexilate 
  Dabigatran etexilate (Pradaxa
®, Boehringer Ingelheim 
GmbH, Ingelheim, Germany) is a new, oral direct thrombin 
inhibitor. It is a prodrug that is rapidly converted into 
dabigatran, which has a half-life of 12–17 hours and is 
mainly (about 80%) excreted renally [15, 20]. Dabigatran 
works by binding to the active site of free and clot-bound 
thrombin; as a result, thrombin’s enzymatic capacity is 
inhibited [21, 22]. 
  Based on successful pivotal phase III clinical trials in 
orthopaedic patients [23-24], dabigatran etexilate (hereafter 
referred to as dabigatran) is now licensed in over 75 
countries, including Europe [25] and Canada [26], for VTE 
prevention following THR and TKR surgery. Pivotal studies 
showed that dabigatran demonstrated similar efficacy and 
safety compared with the parenteral LMWH enoxaparin, as 
prophylaxis following major orthopaedic surgery [23, 24], 
although at high doses it may be associated with 
gastrointestinal bleeding and dyspepsia [27]. Therefore, 
dabigatran provides an oral alternative to the parenteral 
agents (LMWH and fondaparinux). Compared with the oral 
vitamin K antagonist warfarin, which is still recommended 
and used widely in the USA [4], dabigatran has the potential 
to provide a number of benefits, including no food 
interactions and few drug interactions, convenient oral 
administration, no risk of heparin-induced thrombocyto-
penia, and predictable anticoagulant effects that abrogate the 
need for regular anticoagulation monitoring [28]. 
 
Clinical Experience with Dabigatran 
  As a direct result of the European pivotal studies, the 
recently published UK and German guidelines include the 
use of dabigatran or other anticoagulants such as LMWH 
[29]. Although dabigatran is used regularly within the 
German medical system, and is already advocated by a large 
number of clinical centres, no detailed clinical protocols or 
descriptions of its clinical use following THR and TKR have 
(to our knowledge) been described as yet. Therefore, it 
seems appropriate and relevant to review the use of 
dabigatran in clinical practice, comparing the pros and cons 
highlighted by this multicentre evaluation. 
  Representatives from four German centres have shared 
and discussed their clinics’ experiences of introducing 
dabigatran into clinical practice and its routine use to date as 
thromboprophylaxis following primary TKA and THR, 
focusing on: number of patients treated and type of 
thromboprophylaxis provided at the centres; outcomes with 
dabigatran; patient satisfaction with dabigatran and staff 
opinion of dabigatran (Table 1). A distinct evaluation of the 
current use and its comparison with LMWH or warfarin 
included the following: efficacy; ease of use; time saving 
compared with subcutaneous application; patient advantages; 
patient satisfaction level; staff (nurse) satisfaction; 
occurrence of haematoma; pricing and overall complication 
rate. Any difficulties encountered, especially during the 
initial clinical implementation phase, were also recorded for 
each centre. 
Number of Patients Treated and Thromboprophylaxis 
Provided 
  Over 7,200 patients have been treated with dabigatran at 
the four centres; these are: Klinik für Gelenkersatz 
(Garmisch-Partenkirchen); ENDO-Klinik (Hamburg); OCM 
Klinik (Munich); Center for Endoprosthetic and 
Reconstructive Joint Surgery (Charité, Berlin). At the Klinik 
für Gelenkersatz, over 2,500 patients received dabigatran 
between April 2008 and September 2010. The ENDO-Klinik 
treated over 1,500 patients with dabigatran between January 
2009 and March 2010, while dabigatran has been in clinical 
use at the OCM Klinik (Munich) since July 2008, and as of 
May 2010 over 2,600 patients had received the drug. At the 
Center for Endoprosthetic and Reconstructive Joint Surgery, 
dabigatran was prescribed to approximately 600 patients 
between April 2009 and September 2010. As the four centres 
used dabigatran during the same time period, this warranted 
a multicenter evaluation. Individual center patient numbers 
and methods of examination and evaluation are not detailed 
due to their heterogeneity. However, surgeons completed a 
standardized questionnaire to provide the results as described 
and detailed in the text and in Table 1. 
  Dabigatran was directly compared to enoxaparin, as 
enoxaparin was the standard treatment in all centers before 
the study. The criteria for choosing to prescribe dabigatran 
included: no contra-indications to therapy; no previous 
warfarin use; no severe bleeding disease; absence of a 
peridural catheter; the availability of a reduced dose for 
patients aged over 75 years, with renal insufficiency or 
receiving amiodarone therapy. The duration of treatment   
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with dabigatran was in accordance with European guidelines: 
28–35 days for THR patients and 10 days in TKR patients 
[25]. 
  The alternative thromboprophylactic agents routinely 
prescribed in these clinics included enoxaparin (Clexane
® 
[Sanofi Aventis, Paris, France]), heparin (Certoparin
® 
[Novartis, Basel, Switzerland]) and fondaparinux (Arixtra
® 
[GlaxoSmithKline, Brentford, UK]). Patients received these 
alternative medications if they exhibited the contra-
indications listed in the package insert for dabigatran. 
Switching from one therapy to another occurred for several 
reasons. Selected patients switched to dabigatran following 
the removal of the peridural catheter and occasionally due to 
recommendations from family doctors. A switch from 
dabigatran to enoxaparin was also necessary for selected 
patients due to reports of nausea. While nausea is a common 
side effect of surgery/anaesthesia, switching of therapy was 
only needed in a small number of cases (fewer than 20 
patients in the overall cohort). In addition, a small proportion 
of patients in three of the four centres reported a slight 
prolongation in wound secretion, which necessitated a switch 
to LMWH. However, an initial surveillance study including 
over 200 patients by the Endo-Klinik Hamburg did not show 
a significant prolongation of the incision or drainage wound 
when compared with LWMH. 
Safety and Efficacy Outcomes with Dabigatran 
  All advantages and disadvantages associated with the 
implementation of the new drug are summarized in Table 1. 
In general, the efficacy and safety of dabigatran were 
Table  1.  Advantages and Disadvantages Associated with the Implementation and Use of Dabigatran in Clinical Practice, as 
Compared with low Molecular Weight Heparin 
 
  ENDO- 
Klinik 
OCM  
Klinik 
Center for Endoprosthetic  
and Reconstructive Joint Surgery 
Klinik für  
Gelenkersatz 
Advantages 
Good efficacy  •  •  •
1 • 
Comparable efficacy to enoxaparin        • 
Ease of use/oral dosing/single application/fixed flexible dosing  •  •  •
1 • 
Time-saving   •    • 
Can be taken by patients at home  •  •    • 
High patient satisfaction levels  •  •    • 
High staff satisfaction levels      •  •
2 
Lack of haematoma    •    • 
No risk of heparin-induced thrombocytopenia  •  •    • 
No need for regular monitoring of coagulation parameters  •  •    • 
No increase in DVT in first 8 days post-surgery  •  •    • 
No increase in complications such as severe bleeding or need for wound revision  •  •    • 
Reduced dosage available        • 
Good safety profile  •  •  •  • 
Clarity of protocol      •   
Fair pricing      •  • 
Disadvantages 
Time-consuming implementation   •  •    • 
Limitations during spinal anaesthesia  •  •    • 
Not suitable for use following DVT  •  •    • 
No indication for treatment of DVT  •  •    • 
Relative inaccuracy of laboratory coagulation parameters   •  •    • 
No long-term experience  •  •    • 
Severe nausea in some patients requiring change of therapy  •  •    • 
Possible cost disadvantage   •      • 
Large size of capsules        • 
•Either data provided by the clinic supports this statement or an author from the clinic stated that they agree with the statement. 
1Very good; 
2 Mostly. 
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deemed to be good or very good by the clinics and were 
thought to be comparable to the parenteral anticoagulants 
used. Since dabigatran is administered orally as a fixed dose, 
it was found to be easy to use. At three of the centres no 
notable safety complications with dabigatran were reported. 
However, one clinic reported rare cases of intestinal tract 
bleeding in patients receiving dabigatran, but a connection 
between the two was deemed questionable by the clinic. 
Patient Satisfaction with Dabigatran 
  Patient satisfaction with dabigatran in these clinical 
settings was high, and in some centres better patient comfort 
was reported with dabigatran. A number of questions were 
frequently asked by patients, including how dabigatran’s 
efficacy compared to that of enoxaparin, and whether one 
dosing regimen was suitable for all. Satisfaction with 
dabigatran was particularly high in those patients with 
previous experience of LMWH; indeed, dabigatran’s oral 
administration was preferable to the parenteral application of 
LMWH, which can be associated with abdominal 
haematomas. 
  However, some patients complained about the increasing 
number of oral medications that they needed to take 
postoperatively. The extra two capsules (2 x 110 mg), in 
addition to other necessary drugs, such as painkillers and 
anti-inflammatory medications, increase this burden. This is 
particularly a problem in the early postoperative phase, 
which is associated with limited oral receptiveness. 
Staff Opinion of Dabigatran 
  Although the implementation of the drug was initially 
time-consuming for nurses and clinical staff, the ease of use 
once implemented was rated as good. Staff appreciated the 
simple, independent and single daily dose application of 
dabigatran, all of which are likely to aid compliance. The 
fact that routine laboratory monitoring is not required was 
welcomed, as was the option of a reduced dose for specific 
patient groups. 
  Staff questioned the initiation and duration of dabigatran 
treatment and whether adjustment for body weight was 
necessary. It is recommended that dabigatran is initiated as a 
half dose 1–4 hours post-surgery if appropriate levels of 
haemostasis are achieved. However, if this is not possible, 
therapy should be started as a half dose later on during the 
day of surgery or as a full dose on the following day [30]. 
Studies show that delaying the initiation of 220 mg 
dabigatran does not affect efficacy [31]. 
  As shown in a previous study, and confirmed with our 
nursing experience, the two main benefits of oral 
administration were removal of the threat of needle-stick 
injuries and of the need for patient education regarding 
LMWH self-administration in the rehabilitation phase [32]. 
However, it was also highlighted by the nurses that 
subcutaneous drugs, administered by the nurse, might be 
appropriate for some very elderly patients or patients with 
cognitive impairment. 
SUMMARY 
  Thromboprophylaxis is recommended following THR 
and TKR, and there has been a need for safe and effective 
but more convenient anticoagulant therapies. Dabigatran has 
been licensed for this indication in over 75 countries, 
including Europe and Canada. Here, we have documented 
the experiences of four German clinics that have introduced 
dabigatran into routine clinical practice. This was an 
important exercise since the implementation of, and 
experiences with, a drug during trial conditions may differ 
from those in a clinical setting. This experience with over 
7,200 patients should provide useful and relevant 
information for surgeons considering dabigatran for the 
indication discussed. Overall, dabigatran was viewed as an 
effective oral alternative for thromboprophylaxis following 
major orthopaedic surgery, and its discussed advantages are 
likely to improve patient adherence to anticoagulant therapy. 
To simplify general oral VTE prophylaxis for the 
orthopaedic surgeon, we propose that dabigatran should also 
be investigated for trauma or other elective surgical 
interventions involving the lower extremities. 
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